|
|
||||||||
1 School of Biological Sciences, The University of Reading, Whiteknights, Reading RG6 6AJ, UK
2 School of Biomolecular Sciences, Oxford Brookes University, Oxford OX3 OBP, UK
(Requests for offprints should be addressed to P G Knight; Email: p.g.knight{at}reading.ac.uk)
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
FS is a cysteine-rich, single chain glycoprotein encoded by a single gene. It exists as multiple size isoforms as a result of alternate mRNA splicing to generate two core proteins (FS-315 and FS-288) the larger of which is extended at the carboxy terminus. These core proteins undergo further post-translational modifications, including proteolytic cleavage and differential glycosylation to produce the six different isoforms that have been identified in ovarian follicular fluid of pigs and cows (Sugino et al. 1993, 1994, Welt et al. 2002). Although initially characterised as an activin-binding protein, FS also binds with lower affinity to several other TGFß superfamily members including inhibin (Shimonaka et al. 1991) and BMP-4, -6 and -7 (Otsuka et al. 2001, Amthor et al. 2002, Glister et al. 2004) but the extent to which this binding modulates the bioavailability of these ligands requires further investigation.
Evidence suggests that the relative activin tone of a follicle (i.e. the ratio of activin to inhibin and/or FS) is an important determinant of its developmental fate (Hillier 1991, Hillier & Miro 1993) but there have been few direct studies to examine, at the protein level, the changing intrafollicular balance between activin and its opposing factors, inhibin and FS, during follicle development. Since granulosa cells can synthesise multiple FS isoforms with potentially distinct functional roles (Nakamura et al. 1991, Sugino et al. 1994, Schneyer et al. 2000, Welt et al. 2002), a further question that has yet to be addressed is whether the relative abundance of different FS isoforms in bFF vary during follicle development?
Therefore, the aims of the present study were: (1) to provide a detailed analysis of intrafollicular concentrations of inhibin, activin and FS proteins during bovine folliculogenesis; (2) to determine whether the relative abundance of individual FS isoforms varies during antral follicle growth in cattle and, if so, whether such changes are associated with other markers of follicle development including concentrations of E and P; and (3) to investigate whether in vitro exposure of isolated granulosa cells to FSH or IGF modifies the relative abundance of different FS isoforms secreted by the cells.
| Materials and Methods |
|---|
|
|
|---|
Ovaries from approximately 40 randomly cycling cattle ( < 18 month-old) were obtained from an abattoir over a period of several months. Upon arrival in the laboratory each batch of ovaries was placed on ice and antral follicles (n=146) ranging from 220 mm in diameter were removed using dissecting scissors and placed in ice-cold PBS until their diameters were recorded. To provide sufficient bFF sample volumes for analysis, follicles in the smallest (2 mm) size category were pooled (35 per pool) while follicles > 3 mm were processed individually. Follicles were punctured with a needle and bFF recovered by centrifugation (13 000 g for 3 min) and transferred to a fresh tube to which 1% (v/v) protease inhibitor cocktail (Sigma UK Ltd) was added. bFF samples were stored at 20 °C until analysed.
Granulosa cell culture
Mural granulosa cells were harvested from cattle ovaries obtained from an abattoir as described by Glister et al.(2001). Briefly, follicles of 46 mm diameter were dissected, aspirated, hemisected and the granulosa cell layer gently disrupted with the aid of a plastic inoculation loop. Cells were pelleted by centrifugation (800 g for 10 min) and subjected to an osmotic shock treatment to lyse any red blood cells present. Cells were pelleted, resuspended in a small volume of culture medium (McCoys 5A modified medium supplemented with 1% (v/v) antibiotic-antimycotic solution, 10 ng/ml bovine insulin, 2 mM L-glutamine, 10 mM HEPES, 5µg/ml apotransferrin, 5 ng/ml sodium selenite, 0.1% BSA and 107M androstenedione; all purchased from Sigma) and counted using a hemocytometer. Granulosa cells were seeded at a density of 0.5 x 106 viable cells/well in 12-well tissue culture plates (Nunclon; Life Technologies Ltd) containing 1 ml pre-equilibrated culture medium with and without treatments (0.33 ng/ml FSH and 10 ng/ml LR3-IGF-1 alone and in combination; 12 replicate wells per treatment). These dose levels of FSH and LR3-IGF-1 were selected as being optimal on the basis of our previous dose-response studies on bovine granulosa cells (Glister et al. 2001, 2003). Plates were incubated at 38.5 °C in 5% CO2 and 95% air for 6 days. Conditioned medium was removed and replaced with fresh media (with and without treatments) every 2 days. For the final culture period (day 46) BSA was omitted from the culture medium to prevent protein overloading during the immunoblotting procedure. At the end of the 6-day culture period viable granulosa cell number was determined by uptake of neutral red dye (Campbell et al. 1996). For FS immunoblot analysis, conditioned media (day 46 of culture) pooled from 12 replicate wells per treatment were pooled and centrifuged (10 min at 800 g) before desalting and concentrating to 0.1 ml using centrifugal ultrafiltration devices (10 000 MW cut-off; Amicon, Millipore, Bedford, MA, USA). Concentrations of inh-A, act-A, E and total FS were measured in aliquots of pooled conditioned media taken before the desalting/concentration procedure.
Hormone immunoassays
Concentrations of inh-A were determined using the two-site IRMA described by Knight and Muttukrishna (1994). Purified 32 kDa bovine inh-A (Knight et al. 1990) was used as a standard. The detection limit of the assay was 250 pg/ml with mean intra- and inter-assay coefficient of variations (CVs) of 5% and 10% respectively. Act-A levels were measured using a two-site ELISA (Knight et al. 1996). Human recombinant (hr) act-A (NIBSC, Potters Bar, Herts, UK) was used as a standard and the assay sensitivity was 100 pg/ml. Intra- and inter-assay CVs were 4% and 7% respectively. Total FS levels were determined using the ELISA described by Tannetta et al.(1998). Values are expressed in terms of hr-FS preparation provided by the National Hormone and Pituitary Programme (NHPP). Assay sensitivity was 100 pg/ml and intra- and inter-assay CVs were 7% and 9% respectively. Concentrations of P were determined by ELISA (Sauer et al. 1986). The detection limit was 10 pg/ml and intra- and inter-assay CVs were 7% and 10% respectively. Concentrations of E were determined by radioimmunoassay as described previously (Glister et al. 2001). The detection limit of the assay was 1.5 pg/ml and intra- and inter-assay CVs were 4% and 8% respectively.
SDSPAGE/immunoblotting to resolve and quantify individual FS isoforms
Follicular fluid samples were diluted in non-reducing sample buffer (0.125 M TrisHCl, pH 6.8, 10% (w/v) SDS, 30% (w/v) sucrose, 0.02% (w/v) bromophenol blue) and loaded at a concentration of 50 µg total protein/lane (follicles > 3 mm) or 25 µg total protein/lane (follicles
3mm). Each sample was analysed in duplicate on two separate gels. Desalted/concentrated conditioned media samples were diluted 50:50 with non-reducing sample buffer and 20µl/lane loaded. All samples were heated to 95 °C for 5 min and then fractionated on 5% stacking/12.5% resolving SDSPAGE gels (Mighty Small Tall system; Hoefer, San Francisco, CA, USA) run at 10 mA/gel. Proteins were then electrotransferred onto nitrocellulose membrane for 2 h at 10 V using a semi-dry transfer cell (Bio-Rad) and transfer buffer (48 mM Trisbase, 39 mM glycine, 1.3 mM SDS, 20% methanol). Gels were stained with Coomassie blue to check transfer efficiency. After blotting membranes were blocked overnight at 4 °C in PBS containing 5% Blotto and 1% BSA. Membranes were then incubated overnight at 4 °C in PBS containing 5% Blotto, 1% BSA and a mixture of two monoclonal antibodies raised against recombinant human FS-288 (clone 1/1 and 8/1, 0.5µg/ml). Membranes were washed three times in PBS/0.1% azide for 10 min each and then incubated with a 125I-labelled goat-anti mouse secondary antibody (100 000 cpm./ml) at room temperature for 3 h. After washing, membranes were blotted dry using filter paper and wrapped in Saran wrap before being placed on a phosphor screen for 4 days. Western blots were imaged using a Phosphorimager (Molecular Dynamics) and analysed using Image J 1.32J. For quality control purposes, an aliquot of the same pooled bFF preparation was applied to one lane of each gel and carried through the FS immunoblotting procedure. The between gel CV for FS band intensity averaged 10.6%. In each sample the proportion of total FS represented by individual isoforms was calculated by expressing the band intensity for each isoform as a % of the total FS band intensity (i.e. sum of individual band intensities).
Statistical analysis
One-way and two-way ANOVA (with post hoc Fishers PLSD test where appropriate) of log-transformed data were used to evaluate between group differences in intrafollicular steroids, inh-A, act-A, total FS and the proportion of total FS represented by each of the six individual isoforms detected. Where indicated, Fishers protected least significant difference (PLSD) test was used to make individual post hoc comparisons, providing ANOVA gave a significant F ratio. The same analyses were used to assess hormone secretion by cultured granulosa cells. Simple correlation analyses were also used to examine the relationship between some of the above variables. Unless stated otherwise, values are presented as arithmetic means ± S.E.M.
| Results |
|---|
|
|
|---|
As shown in Fig.1a
follicle growth from 26 mm was associated with a several hundred-fold increase in E concentration with the steepest increase between 11 and 20 mm. From 26 mm there was a progressive 6-fold increase in inh-A (P < 0.0001) and 30-fold increase in act-A (P < 0.0001) while FS remained at a uniformly high level from 210 mm (see Fig.1 b, c and d
). From 620 mm, inh-A remained high while concentrations of act-A and FS fell 3-fold (P < 0.001) and 2-fold (P < 0.01), respectively. Correspondingly, act-A/FS ratio (Fig. 1e
) increased 20-fold (P < 0.0001) from 26 mm before falling slightly through to 20 mm (not significant). Act-A/inh-A ratio (Fig. 1f
) increased 6-fold from 26 mm (P < 0.0001) before falling 2-fold from 6 mm to 1720 mm (P < 0.01).
|
A representative immunoblot showing the presence of six different bands of FS immunoreactivity in individual, randomly selected bFF samples is presented in Fig. 2
. These bands had apparent Mr values of 65, 41, 37, 35, 33 and 31 kDa and, considering all follicles analysed, they represented 6, 13, 24, 26, 13 and 17% respectively of total FS immunoreactivity (i.e. sum of each individual immunoblot band intensity). Five of the six immunoreactive FS bands identified in bFF had apparent Mr values within the range corresponding to known molecular isoforms of FS. The weakest band with an apparent Mr of 65 kDa is too large to correspond to full length FS precursor or any known FS isoform and may represent dimerization of individual FS molecules. It was not possible to establish whether this 65 kDa band remained when gels were run under reducing conditions since this abolished binding of the FS antibodies.
|
|
Considering all bFF samples, follicle diameter was positively correlated with E/P ratio (r=0.36; P < 0.0001) and negatively correlated with FS concentration (r= 0.55; P < 0.0001) and act-A/inh-A ratio (r= 0.25; P < 0.01). To further explore the relationship between oestrogenic status and the intrafollicular balance of inhibin, activin and FS, follicles > 6 mm in diameter were arbitrarily assigned two size classes: medium (612 mm) and large (1320 mm). Follicles in each size category were then arbitrarily categorised as having high oestrogenic status (E/P ratio > 5), or low oestrogenic status (E/P ratio < 5).
The resultant mean E/P ratios in the four different follicle categories are shown in Fig. 4a
. With regard to inh-A concentration 2-way ANOVA revealed a highly significant effect of oestrogenic status (P < 0.0001) and a statistical interaction (P < 0.005) between size-class and oestrogenic status (Fig. 4d
). Within the small follicle category inh-A levels were similar in high-oestrogenic follicles and low-oestrogenic follicles but in the large follicle category inh-A levels were 2-fold lower in highly oestrogenic follicles. As shown in Fig. 4b and c
, mean concentrations of both act-A and FS in large follicles were 23-fold lower than in small follicles (P < 0.0001). Act-A was also affected by oestrogen status, being lower in highly oestrogenic follicles, but there were no differences with respect to FS. Likewise there was no effect of oestrogenic status on the relative abundance of the six individual isoforms of FS (data not shown). There were no significant effects of (nor statistical interaction between) follicle size class or oestrogenic status on intrafollicular act-A/FS ratio (Fig. 4e
). However, act-A/inh-A ratio in large follicles was significantly lower than small follicles (P < 0.001) but there was no size-class x oestrogenic status interaction (Fig. 4f
).
|
As shown in Fig. 5
treatment of isolated granulosa cells with FSH alone enhanced secretion of E and inh-A (P < 0.05) while IGF analogue alone enhanced secretion of FS, E, inh-A and act-A (P < 0.05). Co-treatment with FSH and IGF analogue promoted an even greater response. Act-A/FS ratio and act-A/inhibin ratio was also raised by combined treatment with FSH and IGF. A representative FS immunoblot of granulosa cell-conditioned media samples is shown in Fig. 6
. Five of the six different FS isoforms found in bFF were detected (65, 41, 37, 35, 31 kDa) and, considering all samples analysed, these represented 18, 30, 28,16 and 8% of total FS immunoreactivity. However, the relative amount of each FS isoform increased in parallel in response to treatment with FSH and IGF analogue, alone and in combination (Fig. 7a
). Consequently, when the data were expressed on a proportional basis (Fig. 7b
) there was no difference between treatments in the proportion of total FS represented by each individual isoform.
|
|
|
| Discussion |
|---|
|
|
|---|
The present finding that follicle growth from 920 mm was associated with a highly significant 2-fold reduction in total FS concentration in FF, is inconsistent with previous immunohistochemical evidence in cattle, that granulosa cells of large, functionally dominant follicles contain more FS than granulosa cells of smaller or subordinate follicles (Singh & Adams 1998). Indeed, when we classified large (1320 mm) follicles on the basis of E/P ratio, follicles with a high E/P ratio tended (not significant) to have lower FS contents than those with low E/P ratio; there was certainly no indication of a positive association between FS levels and oestrogenicity. In agreement with our data, Li et al.(1997) reported an inverse association between FS concentration in FF and follicle size in pigs. However, analysis of human follicular aspirates revealed no change according to follicle size or functional status (Erickson et al. 1995, Schneyer et al. 2000). Similarly, it was reported that granulosa cell expression of the two alternately spliced FS mRNA transcripts, corresponding to FS-315 and FS-288, did not vary during growth of human follicles from 623 mm (Fujiwara et al. 2001). The explanations for these apparent species differences are not known.
Our observation that antral follicle growth is associated not only with a decrease in total FS concentration in FF but also with a distinct shift in the relative abundance of different FS isoforms is novel and intriguing but, at this stage, we can only speculate as to the functional significance of this finding. While all FS isoforms are capable of binding activin with high affinity, the shorter isoforms, notably FS-288, also have a high affinity for sulphated proteoglycans on the cell surface, longer isoforms (e.g. FS-315) do not (Sugino et al. 1993, 1994). It has been suggested that the shorter membrane-anchored FS isoforms act to sequester activin on the cell surface, while the longer isoforms may bind activin in the circulation and extracellular fluid (Sugino et al. 1994, Schneyer et al. 1997, Wang et al. 2000). Since the relative abundance of the larger 41 and 37 kDa FS isoforms increased during follicle growth while the abundance of the smaller 33 and 31 kDa FS isoforms decreased, this could reflect changing granulosa cell expression of the two FS mRNA splice variants throughout follicle growth. However, a study of human granulosa cells revealed no change in expression (or ratio of expression) of FS-288 and FS-315 mRNA splice variants follicles with follicle size (Fujiwara et al. 2001). An alternative possibility is that the extent of post-translational modification of the two FS core proteins (FS-288 and FS 315) might change as follicles grow. Thus granulosa cells might proteolytically cleave FS-315 into the truncated form (FS-303), or glycosylate FS-315, FS-303 or FS-288 to different extents according to the stage of follicle growth. Thirdly, the relative abundance of different FS isoforms in the FF compartment might be affected by changes in cellular binding, cellular uptake, rate of degradation or rate of exit of FS isoforms through the follicle wall. Thus, the observed decline in the relative abundance of the smaller FS isoforms (33 and 31 kDa) during follicle growth could reflect their selective depletion from FF as a result of enhanced binding to cell surface proteoglycans. Given the substantially (~1000-fold) lower concentration of FS in the peripheral circulation, it is most improbable that the FS isoform distribution pattern in FF is influenced by FS from extra-follicular sources.
While the physiological significance of these multiple FS isoforms remains to be investigated, it is generally assumed that all serve to diminish the association of activins, and perhaps other TGFß superfamily ligands, with their cognate receptors. However, it is possible that in some circumstances FS might serve to enhance presentation of activin and/or other ligands to cell surface receptors (Schneyer et al. 1997), this might be expected when the binding affinity with FS is relatively low, as is the case with BMPs (Iemura et al. 1998, Amthor et al. 2002, Glister et al. 2004). There is also evidence that binding of activin to FS anchored to the cell surface promotes internalization and subsequent lysosomal degradation of activin within the cell (Hashimoto et al. 1997). The presence of a large molar excess of FS over act-A in small antral follicles suggests that FS would be available to bind and potentially modulate the bioavailability of ligands other than act-A, at least in follicles < 5 mm in diameter. In follicles growing beyond 6 mm, act-A increased to a level that would effectively saturate the available FS; given the very high affinity of activin for FS, we predict that this would displace other less avidly-bound FS ligands (e.g. BMPs) in FF, perhaps enhancing their interaction with signalling receptors on the cell surface.
We carried out in vitro experiments on isolated granulosa cells to test the hypothesis that treatment with known FS secretagogues (FSH, IGF) would modify the relative abundance of different FS isoforms, secreted by the cells and thus help explain, at least in part, the shift in the FS isoform distribution pattern observed during follicle development. In confirmation of our previous findings (Glister et al. 2001, 2003, 2004) there was a clear-cut enhancement of inh-A, act-A and total FS secretion in response to treatment with FSH and IGF. Combined treatment with FSH and IGF also increased act-A/FS ratio and act-A/inh-A ratio, as was observed during follicle growth from 46 mm. However, the relative abundance of the five different FS isoforms detected in cell-conditioned medium was remarkably constant across treatments, leading us to reject this hypothesis. Since FSH and IGF treatment promoted a concomitant increase in E secretion by the granulosa cells (up to 30-fold), this in vitro observation actually corroborates our ex vivo analysis of bFF samples in which we found no relationship between oestrogenic status and follicle isoform distribution pattern in bFF. Rather, follicle size was the key factor affecting the relative abundance of the different FS isoforms in bFF.
The gradual decline in act-A concentration and act-A/inh-A ratio we observed in bFF during follicle growth from 720 mm supports the proposal of Hillier & Miro (1993) that the relative inhibin tone increases as follicles approach pre-ovulatory status. In human follicles, this shift in inhibin tone is mainly due to an increase in inh-B rather than inh-A (Magoffin & Jakimiuk 1998). In bovine follicles, however, concentrations of inh-B are very much lower than inh-A concentrations, questioning the physiological relevance of inh-B in cattle (Knight & Glister 2003). Despite the clear increase in inh-A during follicle growth from 210 mm, classification of large (1220 mm) follicles on the basis of E/P ratio showed an inverse associated between E/P ratio and inh-A concentration. This observation accords with previous studies in cattle (Guilbault et al. 1993, Sunderland et al. 1996) and further supports in vitro evidence that inhibin may have an inhibitory effect on E secretion by bovine granulosa cells (Jimenez-Krassel et al. 2003).
To extend the present study we are currently analysing bFF samples harvested from the ovaries of cycle-synchronised cattle subjected to daily ovarian ultrasound monitoring. We have also isolated the five different FS isoforms (31 41 kDa) from pooled bFF and are assessing their biological potencies using a bovine theca cell-based bioassay. It is anticipated that this additional information will shed further light on the intriguing finding of a follicle size-dependent shift in intrafollicular FS concentration and isoform distribution pattern. In conclusion, a marked increase in intrafollicular activin tone accompanies bovine follicle growth from 36 mm in diameter, and this corresponds to the stage at which the FSH-dependent follicle selection mechanism is considered to operate in this species.
| Acknowledgements |
|---|
| References |
|---|
|
|
|---|
Alak BM, Coskun S, Friedman CI, Kennard EA, Kim MH & Seifer DB 1998 Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Fertility and Sterility 70 11261130.[CrossRef][ISI][Medline]
Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E & Patel K 2002 Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Developmental Biology 243 115127.[CrossRef][ISI][Medline]
Campbell BK, Scaramuzzi RJ & Webb R 1996 Induction and maintenance of ooestradiol and immunoreactive inhibin production with FSH by ovine granulosa cells cultured in serum-free media. Journal of Reproduction and Fertility 106 716.[Abstract]
Erickson GF, Chung DG, Sit A, DePaolo LV, Shimasaki S & Ling N 1995 Follistatin concentrations in follicular fluid of normal and polycystic ovaries. Human Reproduction 10 21202124.
Findlay JK 1993 An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis. Biology of Reproduction 48 1523.[Abstract]
Findlay JK & Drummond AE 1999 Regulation of the FSH Receptor in the Ovary. Trends in Endocrinology and Metabolism 10 183188.[CrossRef][ISI][Medline]
Fortune JE, Rivera GM & Yang MY 2004 Follicular development: the role of the follicular microenvironment in selection of the dominant follicle. Animal Reproduction Science 8283 109126.
Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A & Schneyer A 2001 Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. Journal of Clinical Endocrinology and Metabolism 86 42064215.
Glister C, Tannetta DS, Groome NP & Knight PG 2001 Interactions between follicle-stimulating hormone and growth factors in modulating secretion of steroids and inhibin-related peptides by nonluteinized bovine granulosa cells. Biology of Reproduction 65 10201028.
Glister C, Groome NP & Knight PG 2003 Oocyte-mediated suppression of follicle-stimulating hormone- and insulin-like growth factor-induced secretion of steroids and inhibin-related proteins by bovine granulosa cells in vitro: possible role of transforming growth factor
. Biology of Reproduction 68 758765.
Glister C, Kemp CF & Knight PG 2004 Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 127 239254.
Glister C, Richards SL & Knight PG 2005 Bone morphogenetic proteins (BMP) -4, -6 and -7 potently suppress basal and LH-induced androgen production by bovine theca interna cells in primary culture: could ovarian hyperandrogenic dysfunction be caused by a defect in thecal BMP signaling? Endocrinology 146 18831892.
Gong JG, Campbell BK, Bramley TA, Gutierrez CG, Peters AR & Webb R 1996 Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist. Biology of Reproduction 55 6874.[Abstract]
Guilbault LA, Matton P, Rouillier P, Glencross RG, Beard AJ & Knight PG 1993 Relationships between the level of atresia and inhibin contents (
-subunit and
ß dimer) in morphologically dominant follicles during their growing and regressing phases of development in cattle. Biology of Reproduction 48 268276.[Abstract]
Hasegawa Y, Miyamoto K, Abe Y, Nakamura T, Sugino H, Eto Y, Shibai H & Igarashi M 1988 Induction of follicle-stimulating hormone receptor by erythroid differentiation factor on rat granulosa cells. Biochemical and Biophysical Research Communications 156 668674.[CrossRef][ISI][Medline]
Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y & Sugino H 1997 A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. Journal of Biological Chemistry 272 1383513842.
Hillier SG 1991 Regulatory functions for inhibin and activin in human ovaries. Journal of Endocrinology 131 171175.[ISI][Medline]
Hillier SG & Miro F 1993 Inhibin, activin, and follistatin. Potential roles in ovarian physiology. Annals of the New York Academy of Science 28 2938.
Hsueh AJ, Dahl KD, Vaughan J, Tucker E, Rivier J, Bardin CW & Vale W 1987 Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis. PNAS 84 50825086.
Iemura S, Yamaoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H & Ueno N 1998 Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Developmental Biology 95 93379342.
Jimenez-Krassel F, Winn ME, Burns D, Ireland JL & Ireland JJ 2003 Evidence for a negative intrafollicular role for inhibin in regulation of oestradiol production by granulosa cells. Endocrinology 144 18761886.
Knight PG & Muttukrishna S 1994 Measurement of dimeric inhibin using a modified two-site immunoradiometric assay specific for oxidized (Met O) inhibin. Journal of Endocrinology 141 417425.[Abstract]
Knight PG & Glister C 2001 Potential local regulatory functions of inhibins, activins and follistatin in the ovary. Reproduction 121 503512.[Abstract]
Knight PG & Glister C 2003 Local roles of TGF-beta superfamily members in the control of ovarian follicle development. Animal Reproduction Science 78 165183.[CrossRef][ISI][Medline]
Knight PG, Castillo RJ, Glencross RG, Beard AJ & Wrathall JHM 1990 Isolation of bovine ovarian inhibin, its immunoneutralization in vitro and immunolocalization in bovine ovary. Domestic Animal Endocrinology 7 299313.[CrossRef][ISI][Medline]
Knight PG, Muttukrishna S & Groome NP 1996 Development and application of a two-site enzyme immunoassay for the determination of total activin-A concentrations in serum and follicular fluid. Journal of Endocrinology 148 267279.[Abstract]
Li MD, DePaolo LV & Ford JJ 1997 Expression of follistatin and inhibin/activin subunit genes in porcine follicles. Biology of Reproduction 57 112118.[Abstract]
Magoffin DA & Jakimiuk AJ 1998 Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women. Human Reproduction 12 17141719.
Mihm M, Crowe MA, Knight PG & Austin EJ 2002 Follicle wave growth in cattle. Reproduction in Domestic Animals 37 191200.[CrossRef][ISI][Medline]
Nakamura T, Sugino K, Titani K & Sugino H 1991 Follistatin: an activin-binding protein, associates with heparin sulphate chains of proteoglycans on follicular granulosa cells. Journal of Biological Chemistry 266 1943219437.
Otsuka F, Moore RK & Shimasaki S 2001 Biological function and cellular mechanism of bone morphogenetic protein-6 in the ovary. Journal of Biological Chemistry 276 3288932895.
Sauer MJ, Foulkes JA, Worsfold A & Morris BA 1986 Use of progesterone 11-glucuronide-alkaline phosphatase conjugate in a sensitive microtitre-plate enzyme immunoassay of progesterone in milk and its application to pregnancy testing in dairy cattle. Journal of Reproduction and Fertility 76 375391.[Abstract]
Schneyer AL, Wang QF, Weiss J, Boepple, Hall J, Khoury, Taylor A, Pralong F, Sluss P & Crowley WF 1997 Follistatin physiology and potential mechanisms of action in the human. In Inhibin, activin and follistatin: regulatory functions in system and cell biology, pp 2838. Eds T Auno, H Sugino & W Vale. New York, USA: Serono Symposia.
Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM & Taylor AE 2000 Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. Journal of Clinical Endocrinology and Metabolism 85 33193330.
Shimasaki S, Moore RK, Otsuka F & Erickson GF 2004 The bone morphogenetic protein system in mammalian reproduction. Endocrine Reviews 25 72101.
Shimonaka M, Inouye S, Shimasaki S & Ling N 1991 Follistatin binds to both activin and inhibin through the common beta subunit. Endocrinology 128 33133315.[Abstract]
Silva CC & Knight PG 1998 Modulatory actions of activin-A and follistatin on the developmental competence of in vitro-matured bovine oocytes. Biology of Reproduction 58 558565.
Singh J & Adams GP 1998 Immunohistochemical distribution of follistatin in dominant and subordinate follicles and the corpus luteum of cattle. Biology of Reproduction 59 561570.
Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K & Sugino H 1993 Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. Journal of Biological Chemistry 268 1557915587.
Sugino H, Sugino K & Nakamura T 1994 The activin-binding protein. In Inhibin and inhibin-related proteins, pp 6980. Eds H Burger, J Findlay, D Robertson, D de Krester, F Petraglia. Rome, Italy: Ares-Serono Symposia Publications.
Sunderland SJ, Knight PG, Boland MP, Roche JF & Ireland JJ 1996. Alterations in intrafollicular levels of different molecular mass forms of inhibin during development of follicular- and luteal-phase dominant follicles in heifers. Biology of Reproduction 54 453462.[Abstract]
Tannetta DS, Feist SA, Bleach ECL, Groome NP, Evans LW & Knight PG 1998 Effects of active immunization of sheep against an amino terminal peptide of the inhibin
C subunit on intrafollicular levels of activin A, inhibin A and follistatin. Journal of Endocrinology 157 157168.[Abstract]
Wang Q, Keutmann HT, Schneyer AL & Sluss PM 2000 Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin-A binding and structural consequences of activin binding to native proteins. Endocrinology 141 31833193.
Webb R, Campbell BK, Gaverick HA, Gong JG, Gutierrez CG & Armstrong DG 1999 Molecular mechanisms regulating follicular recruitment and selection. Journal of Reproduction and Fertility supplement 54 3348.
Welt C, Sidis Y, Keutmann H & Schneyer A 2002 Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Experimental Biology and Medicine 227 724752.
Wrathall JH & Knight PG 1995 Effects of inhibin-related peptides and ooestradiol on androstenedione and progesterone secretion by bovine theca cells in vitro. Journal of Endocrinology 145 491500.[Abstract]
Xiao S, Robertson DM & Findlay JK 1992 Effects of activin and follicle-stimulating hormone (FSH)-suppressing protein/follistatin on FSH receptors and differentiation of cultured rat granulosa cells. Endocrinology 131 10091016.[Abstract]
Ying S 1988 Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocrine Reviews 9 267293.[Abstract]
Received 1 November 2005
Accepted 7 November 2005
This article has been cited by other articles:
![]() |
M A Beg and O J Ginther Follicle selection in cattle and horses: role of intrafollicular factors. Reproduction, September 1, 2006; 132(3): 365 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G Knight and C. Glister TGF-{beta} superfamily members and ovarian follicle development. Reproduction, August 1, 2006; 132(2): 191 - 206. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |